SEQUENT SCIENTIFIC LTD.
NSE : SEQUENTBSE : 512529ISIN
CODE : INE807F01027Industry : Pharmaceuticals & DrugsHouse
: Sequent
BSE125.60-0.45 (-0.36 % )
PREV CLOSE (Rs.) 126.05
OPEN PRICE (Rs.) 126.35
BID PRICE (QTY) 125.25 (7 )
OFFER PRICE (QTY) 125.65 (398 )
VOLUME 42462
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE125.70 -0.35 (-0.28 % )
PREV CLOSE(Rs.) 126.05
OPEN PRICE (Rs.) 126.05
BID PRICE (QTY) 125.50 (135 )
OFFER PRICE (QTY) 125.70 (989 )
VOLUME 184905
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 18-Apr-2024 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | Allotment of Equity Shares under Sequent Scientific Limited Employee Stock Option Plan 2020 |
| 04-Apr-2024 | Sequent Scientific informs about resignation of Managing Director | <p style="text-align: justify;">Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations') Sequent Scientific has informed Sharat Pandurang Narasapur, Jt. Managing Director has through his letter dated April 03, 2024 has tendered his resignation from the employment of the Group for personal reasons. Consequently, Sharat Pandurang Narasapur has resigned as a Jt. Managing Director (MD) from the Board of Directors of the Company, with effect from the close of business hours on April 30, 2024. Pursuant to the above, Sharat Pandurang Narasapur shall cease to be a Member of the Corporate Social Responsibility Committee of the Board effective close of business hours on April 30, 2024. However, he shall continue as a Director (Nonexecutive) in the Board of the wholly owned subsidiary Alivira Animal Health. Further, the information required in terms of Regulation 30 read with Schedule III – Para A (7) of Part A of the SEBI Listing Regulations and SEBI Master Circular bearing Ref. No. SEBI/HO/CFD/ PoD2/CIR/P/2023/120 dated July 11, 2023 is enclosed as ‘Annexure-I' to this letter. The company has attached the letter of resignation received from Sharat Pandurang Narasapur.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 08-Feb-2024 | Sequent Scientific to sell plot located in Ambernath Industrial Area | <p style="text-align: justify;">Sequent Scientific has executed Deed of assignment on February 08, 2024, for sale of Plot No 7 in the Ambernath Industrial Area, situated at Village Morivali, within the registration Sub District Kalyan, District Thane, at value Rs 7.82 crore (including taxes). The area of the Plot is admeasuring about 7,481 square metres.</p><p style="text-align: justify;">Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. </p><div style="text-align: justify;"><br></div> |
| 13-Nov-2023 | Sequent Scientific informs about transcript of earnings call | <p style="text-align: justify;">Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sequent Scientific has informed that it enclosed the Earnings Call Transcript pertaining to the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023. The same is also available on the Company's website at https://www.sequent.in/pdf/financial/2023- 2024/Sequent%20Transcript_Nov07_2023.pdf.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div><br></div> |
| 25-Sep-2023 | USFDA completes inspection at Sequent Scientific's Visakhapatnam manufacturing facility | <p style="text-align: justify;">The United States Food and Drug Administration (USFDA) has completed inspection at Sequent Scientific's manufacturing facility situated at Visakhapatnam, Andhra Pradesh between September 18, 2023 and September 22, 2023. At the end of the inspection, the company has been issued a Form 483 with one observation. The observation is procedural in nature. The company will respond to the USFDA within the stipulated timeline and work closely with them to address the observation at the earliest.</p><p style="text-align: justify;">Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. </p><div style="text-align: justify;"><br></div> |
| 15-Sep-2023 | Sequent Scientific gets nod to sell API facility in Tarapur | <p style="text-align: justify;">Sequent Scientific has received approval to sell/ transfer its API facility situated at Plot Nos. 136, 137, 138, 139, 140, 141, 150, 151 & W-152, MIDC, Tarapur, Boisar Dist. Thane, Maharashtra, India. The Board of Directors at its meeting held on September 14, 2023 considered and approved the same. </p><p style="text-align: justify;">Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. </p> |
| 17-Aug-2023 | Sequent Scientific informs about rectification of inadvertent typographical error | <div>Sequent Scientific has informed that on Page No. 7 of the Notice of 38th Annual General Meeting (‘AGM'), the last line of the table containing the details of the current status of options granted, vested, lapsed, exercised and outstanding to be read as ‘Granted but not vested' instead of ‘Vested but not exercised'.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 11-Aug-2023 | Sequent Scientific informs about audio recording of earnings call | <div style="text-align: justify;">Sequent Scientific has informed that the audio recording of the earnings call and earnings presentation made on August 11, 2023, on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023, is available on the Company's website.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 08-Aug-2023 | Sequent Scientific informs about appointment of director | <p style="text-align: justify;">Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, Sequent Scientific has informed that the Board of Directors based on the recommendation of the Nomination and Remuneration Committee held on August 07, 2023, approved the appointment of Dr. Hari Babu Bodepudi (DIN: 01119678) as Additional Director (Non-Executive Non-Independent) with effect from August 07, 2023. Dr. Hari Babu Bodepudi will hold office until the conclusion of the ensuing Annual General Meeting of the Company and the Company will be seeking approval of the shareholders at the ensuing Annual General Meeting. Brief profile and other Information of aforesaid Director pursuant to SEBI Circular bearing reference SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is mentioned in ‘Annexure A' as enclosed.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE. </p> |
| 17-May-2023 | Sequent Scientific informs about conference call | <p style="text-align: justify;">Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sequent Scientific has informed that the Company has, as a part of its investors engagement activities, scheduled a conference call with the Analysts / Investors on Wednesday, May 24, 2023 at 09:00 am to discuss its Q4FY23 financial results. The Conference call details are enclosed.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div style="text-align: justify;"><br></div> |
